The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate. This basic-helix-loop-helix-leucine-zipper (bHLHzip) protein is critical for melanocyte cell-fate choice during commitment from pluripotent precursor cells in the neural crest. Its role in differentiation pathways has been highlighted by its potent transcriptional and lineage-specific regulation of the three major pigment enzymes: tyrosinase, Tyrp1, and Dct as well as other pigmentation factors. However, the cellular functions of MITF seem to be wider than differentiation and cell-fate pathways alone, since melanocytes and melanoma cells appear to require an expression of this factor. Here, we discuss the transcriptional networks in which MITF is thought to reside and describe signaling pathways in the cell which impinge on MITF. Accumulating evidence supports the notion that MITF is involved in survival pathways during normal development as well as during neoplastic growth of melanoma.
The microphthalamia-associated transcription factor (MITF) is an integral transcriptional regulator in melanocyte, the lineage from which melanoma cells originate. This basic-helix-loop-helix-leucine-zipper (bHLHzip) protein is critical for melanocyte cell-fate choice during commitment from pluripotent precursor cells in the neural crest. Its role in differentiation pathways has been highlighted by its potent transcriptional and lineage-specific regulation of the three major pigment enzymes: tyrosinase, Tyrp1, and Dct as well as other pigmentation factors. However, the cellular functions of MITF seem to be wider than differentiation and cell-fate pathways alone, since melanocytes and melanoma cells appear to require an expression of this factor. Here, we discuss the transcriptional networks in which MITF is thought to reside and describe signaling pathways in the cell which impinge on MITF. Accumulating evidence supports the notion that MITF is involved in survival pathways during normal development as well as during neoplastic growth of melanoma. Oncogene (2003 Oncogene ( ) 22, 3035-3041. doi:10.1038 Keywords: MITF; melanoma; development; melanocyte; survival Elucidation of molecular pathways that govern, or are essential for, the development of melanoma may significantly aid both our understanding of disease pathogenesis and the development of improved therapies for this devastating disease. The incidence of melanoma is rapidly increasing, but therapeutic options remain severely limited. Owing to its propensity for vertical growth with deep invasion, many melanomas metastasize early, and metastatic melanoma is rarely curable. The main focus of this review is the microphthalamia-associated transcription factor (MITF) and its function in both melanocytes, the dedicated pigment cells, and in melanoma cells. MITF's importance in the melanocyte lineage is manifested by observations that mice with mutations in this gene are white because of complete absence of melanocytes. Although expression of many melanocytic markers may be lost in malignant melanoma, expression of MITF appears to be maintained in most if not all such tumors (King et al., 1999; Salti et al., 2000; Bunsam et al., 2001) , thus providing MITF as a sensitive diagnostic marker for melanoma and suggesting that it may play a functional role in the biology of melanoma.
Genetics of MITF in the pigment cells
The MITF gene was first discovered as a spotted mutant mouse in the 1940s (Hertwig, 1942) . Among the numerous mouse coat color mutants discovered over the past century, MITF was one of a smaller subset, which was histologically characterized by loss of melanocytes, rather than defective pigmentation within viable melanocytes. The MITF gene was cloned in 1993 by Arnheiter and colleagues on the basis of a transgenic insertion into the MITF locus (Hodgkinson et al., 1993) . In addition to defects in pigment cells of the skin, eye, hair follicles, and inner ear, severe dominant mutants of this gene also affected several other cell types such as bone resorbing osteoclasts, retinal pigment epithelial cells, and mast cells (Steingrı´msson et al., 1994) . In humans, germline heterozygous mutations of the MITF gene are associated with the congenital pigmentation/ deafness condition, Waardenburg Syndrome (WS) type IIA (Hughes et al., 1994; Tassabehji et al., 1994; Nobukuni et al., 1996) , in which affected individuals display variable degrees of pigmentation dilution and associated deafness because of melanocyte defects in the inner ear (for a review see Price and Fisher, 2001 ). The genetic traits that are observed in these human congenital disorders are because of loss of one allele of MITF, or expression of dominant-negative alleles as in Tietz syndrome. This latter syndrome is a subtype of WS type IIA, exhibiting a more severe phenotype wherein affected patients display more severe deafness and pigment disturbances Smith et al., 2000) .
The MITF gene has been mapped to chromosome 6 in mouse and chromosome 3p12.3-14.1 in humans, which spans nine highly conserved exons that encode a transcription factor of the basic-helix-loop-helix-leucine-zipper family (bHLHzip). There are at least six isoforms of MITF designated by their unique 5 0 ends arising from multiple alternative promoter and initial exon usage. All MITF isoforms contain common downstream exons 2-8, except for an alternative splice acceptor that adds or deletes six amino acids shortly before the basic domain (for a review see Shibahara et al., 2001) . The MITF-M isoform is exclusive to the melanocyte-lineage because of expression from a unique melanocyte-restricted promoter/enhancer. Given that melanocytes are not essential for organismal viability, many mutant alleles of MITF have been identified in mouse, human, and other species (for a review see Nakamura et al., 2002) . Certain mutations in the MITF gene produce altered pigmentation patterns, such as MITF mi-b that yields a brown mouse in heterozyogotic state (Steingrı´msson et al., 1996) and MITF mi-vit that displays age-dependent premature graying because of melanocyte loss in homozygotes (Lerner et al., 1986) to name a few. The plethora of MITF mouse mutants not only leads to gradual loss of pigmentation, but also severely impacts the survival/commitment of melanoblast precursors during development. This unique collection of mouse mutations has made it possible to study multiple genetic pathways that regulate pigmentation and the function of the melanocyte (for reviews see Goding, 2000; Tachibana, 2000) .
MITF as a key transcription factor in the pigment biosynthesis pathway
Melanocytes synthesize melanin, which is then transported to the neighboring keratinocytes. Pigment synthesis involves the conversion of tyrosine to melanin. A rate-limiting step in pigment production is catalyzed by the enzyme tyrosinase, which is transcriptionally regulated via a tissue-restricted cis-acting promoter containing a canonical E-box (Ganss et al., 1994; Bertolotto et al., 1996) . Identical E-boxes are also found in the promoters of the two other key pigment enzymes tyrosinase-related protein 1 (Tyrp1) and dopachrome tautomerase (Dct), suggesting a conserved mode of transcriptional regulation (Lowings et al., 1992; Yokoyama et al., 1994; Yasumoto et al., 1997; Bertolotto et al., 1998b) . In vitro experiments have shown that these conserved sequences are bound and potently transactivated by the tissue-restricted transcription factor MITF. Although the full functionality of the conserved E-box site remains to be ascertained, MITF shows high preferential binding to the canonical E-box CACGTG as well as the nonpalindromical CACATG (Bentley et al. 1994; Hemesath et al., 1994; Yasumoto et al., 1994) . MITF binds DNA as a homo-or heterodimer with TFE3, TFEB, or TFEC, which together constitute the MiT-family of bHLHzip-proteins (Hemesath et al., 1994) . Importantly, the dominant-negative alleles of MITF preserve dimerization capacity but lose (or severely compromise) DNA binding via mutations in DNA-contacting amino acids. Additional more subtle differences among the various mutant alleles of MITF involve altered nuclear localization, alternative splice acceptor site usage, and other molecular lesions. Of note, certain nonmelanocyte lineages, such as osteoclasts, are severely abnormal in mice harboring homozygous dominant-negative MITF mutations, but much less affected by null mutations. This effect is likely because of the ability of dominant-negative MITF mutants that titrate out other MiT family members, such as TFE3 in osteoclasts (Weilbaecher et al., 1998 (Weilbaecher et al., , 2001 Steingrı´msson et al., 2002) .
In response to external stimuli, multiple signals are generated by nonmelanocytic cells of the epidermis, which communicate a pigmentation response to the basal melanocyte population. Alpha-melanocyte stimulating hormone (a-MSH) is one such peptide hormone that has been suggested to modulate the pigment response. Studies have shown a role of a-MSH in promoting pigment synthesis (Fuller et al., 1987; Aroca et al., 1993) . a-MSH binds to the melanocortin 1 receptor (MC1r), which is a member of the seventransmembrane receptor family that activates adenyl cyclase via G-protein signaling. In vitro, the effects of a-MSH can be mimicked by drugs such as forskolin, IBMX, and cholera toxin, indicating that a-MSH functions mainly through elevating cyclic-adenosine monophosphate (cAMP) levels in the cell (Wong and Pawelek, 1975; Abdel-Malek et al., 1985) . Although cAMP triggers numerous downstream effects, one important target is the MITF gene, which is transcriptionally upregulated by cAMP signaling in a melanocyte-restricted fashion, thus linking extracellular signals to MITF expression and the transcriptional regulation of pigmentation (Bertolotto et al., 1998a; Price et al., 1998b) .
MITF-M is critical for the melanocyte fate in the neural crest population
Melanocytes originate from a transient population of neural-crest-derived pluripotent cells. These cells receive environmental signals that dictate their cell-fate choice. MITF's pivotal position in melanocyte development is manifested by the tight signal-responsive nature of the MITF melanocyte-restricted promoter/enhancer. Functional analyses of the MITF promoter have revealed that it is regulated by several transcriptional regulators involved in cell-fate decisions for neural crest cells. Of particular importance is the Wnt-signaling pathway, which has been of immense interest for studies of development as well as cancer (for reviews see Wodarz and Nusse, 1998; Hecht and Kemler, 2000; Polakis, 2000; van Noort and Clevers, 2002) . The secreted Wntproteins serve as ligands for the seven-transmembrane Frizzled-family of receptors (FZD) (Yang-Snyder et al., 1996) . The Wnt-signaling pathway converges on the TCF/LEF family of architectural HMG-domain factors that coordinate transcriptional activity by recruiting the effector b-catenin to the nucleus as a coactivator. In the absence of Wnt-signals, cytoplasmic b-catenin is targeted for degradation via phosphorylation by GSK3b in a multicomponent complex, which includes axin and the adenomatous polyposis coli (APC) protein. Wntsignals operate during neural crest specification and for the expansion of this population (Ikeya et al., 1997) . In zebrafish, Wnt has been shown to promote melanocytic differentiation (Dorsky et al., 1998) with MITF as Wnt's downstream effector (Dorsky et al., 2000) . These observations have been complemented in higher vertebrates including mouse neural crest cells where Wnt-1 via b-catenin promotes melanocyte differentiation and expansion as well as in chick (Jin et al., 2001) . Collectively, these studies have placed the Wnt-signaling pathway as a key cue that stimulates melanocytic diffentiation. The role for this pathway in malignancies of the melanocytic lineage is less certain. Activating mutations in b-catenin have been described in a significant fraction of melanoma cell lines (Rubinfeld et al., 1997) . Among primary melanomas, a significant fraction displays nuclear b-catenin, indicating aberrant Wnt pathway activation, but without mutations in b-catenin itself (Rimm et al., 1999) .
During melanocyte development, additional key transcription factors include SOX10, an SRY-related high-mobility-group (HMG)-domain factor, and PAX3, a paired-box-homeodomain transcription factor. Mutations in SOX10 and PAX3 produce WS with extensive overlap in the melanoycte defects as seen with MITF mutations (Baldwin et al., 1992; Tassabehji et al., 1993) (Figure 1) . Specifically, distinct PAX3 mutations lead to either WS type 1 or type 3, conditions that manifest craniofacial malformations with or without limb abnormalities, respectively, in addition to auditory and pigmentation deficiencies. Furthermore, SOX10 mutations are associated with Waardenburg-Shah syndrome (also referred to as WS type 4) exhibiting Hirschsprung's megacolon from incomplete development of enteric ganglia (another neural-crest-derived lineage) together with the melanocytic features of WS (Pingault et al., 1998) . WS type 4 arises from truncating deletions in the SOX10 transcript that preserves the HMG DNAbinding domain but results in loss of the transactivation domain. Mutations in the endothelin receptor-B gene (Ednrb) or its ligand endothelin-3 (ET-3) display the identical syndrome (WS type 4) as SOX10 mutations. Given the phenotypic overlap of mutations in these genes, it is likely that SOX10 and ET-3 reside in a common signaling pathway. ET-3 and its receptor, Ednrb, are required for normal differentiation and development of melanocytes and Auerbach plexus cells, the enteric ganglia of the gut (for a review see McCallion and Chakravarti, 2001) . Ednrb is a G-protein-coupled receptor of the seven-transmembrane family that is thought to modulate cAMP levels (Fuchs et al., 2001) and activate the RAS-MAP-kinase pathway (Imokawa et al., 1996) . The temporal need for Ednrb in melanocyte and enteric ganglia has been elegantly examined using engineered mice (Shin et al., 1999) in which inducible expression of Ednrb identified a critical period between embryonic days 10 and 12.5 for the development of these two lineages.
All the factors so far identified as genetic causes of human WS converge on MITF. The PAX3 and SOX10 genes (Watanabe et al., 1998; Bondurand et al., 2000; Lee et al., 2000; Potterf et al., 2000; Verastegui et al., 2000) as well the Wnt-signaling pathway (Dorsky et al., 2000; Takeda et al., 2000b) potently activate the MITF-M promoter. These factors transactivate the MITF-M promoter/enhancer in a manner that may involve formation of coordinated transcriptional complexes, although the nature of such interactions is incompletely understood (Figure 2) . Recently, an additional layer of regulation on the promoter/enhancer has been identified via the interaction of MITF with the TCF/LEF-member LEF-1 specifically . Interestingly, this interaction appears to have a sigmoidal transcriptional activation curve on the MITF-M promoter/ enhancer , suggestive of a dual role of this interaction for both transactivation as well as autofeedback repression. MITF's role in melanocyte cell fate is further emphasized by the zebrafish MITF orthologue, nacre, which can, when misexpressed, lead to aberrant pigment cell differentiation in the fish (Lister et al., 1999) . In vitro, constitutively expressed MITF has been shown to convert a subclone of murine fibroblasts to melanocytelike cells . In the mouse, MITF mutations result in a reduction of absolute numbers of melanocyte precursor cells (Hornyak et al., 2001) . In contrast, retinal pigment epithelial cells (RPE) that are not neural crest in origin survive severe MITF mutations (Nakayama et al., 1998) , albeit without pigment and with evidence of hyperproliferation and neuroretinal transdifferentiation.
Signaling and MITF: regulation by post-translational modification
Mice carrying mutations in the gene encoding the protooncogene c-Kit or the gene encoding its ligand, stem cell factor (Scf), exhibit a profound coat color phenotype because of loss of viable melanocytes (Russell, 1979; Mayer, 1979) , providing genetic evidence that this pathway might converge with that of MITF. Mutations in the Kit-receptor in humans are associated with piebaldism (Giebel and Spritz, 1991) , an inherited condition resulting in patchy pigmentation and anemia. Activation of the Kit receptor with Scf stimulates the classical MAP kinase pathway in which activated ERKs phosphorylate Ser73 of MITF . This phosphorylation enables recruitment of the transcriptional coactivator p300 (Price et al., 1998a) and also, together with p90 RSK -mediated phosphorylation at Ser409, targets MITF for ubiquitin modification and proteasome-mediated degradation (Wu et al., 2000; Xu et al., 2000) . Thus, the Kit signaling pathway modulates both transactivation potential and stability of MITF, consistent with a need for tight homeostatic control of this transcription factor.
Another important signaling molecule, GSK3b, resides downstream of several signaling pathways, and has been suggested to modulate the transcriptional response of MITF. Along these lines, serine 298 of MITF, a GSK3b phosphoacceptor site, was found to be mutated to proline in a WS type 2 patient (Tassabehji et al., 1995; Takeda et al., 2000a) . Absence of this serine abrogated DNA binding and transcriptional activity of MITF on the tyrosinase model promoter in vitro. While multiple post-translational modifications have thus been identified on MITF, in vivo assays are needed to determine the roles of these events on the activity and stability of MITF within animals.
MITF guards survival of melanocytes and melanoma cells
While the Kit pathway is clearly essential for normal melanocyte development, little is known about its downstream effectors in the melanocyte lineage, aside (Busca et al., 2000) from the known activation of pathways triggered by receptor tyrosine kinases. Mice engineered to express a Kit receptor selectively defective for PI3-kinase/AKT signaling are noteworthy for the normal development of melanocytes, despite severe defects in other Kit-dependent lineages (Blume-Jensen et al., 2000) . This is in sharp contrast to Kit-null mutant mouse, which displays severe loss of melanocytes (Cable et al., 1995; Mayer, 1979; Russell, 1979) . Interestingly, engineered Kit-null neural crest cultures can sustain melanoblast survival (Hou et al., 2000) through activation of the endothelin pathway that converges with the MAPK pathway like that of Kit (Imokawa et al., 1996) . Furthermore, heterozygosity of the tumor-suppressor neurofibrinogen-1, a known negative regulator of RAS-MAPK pathway, gives a partial rescue of Kit-mutations in the mouse (Ingram et al., 2001) . These data collectively suggest that the classical RAS-MAPK pathway mediates key survival signals downstream of Kit during melanocyte development. To this end, a genome-wide approach to identification of MITF target genes in the setting of Kit activation in melanocytes was conducted and found to reveal a transcriptional regulation of the proto-oncogene and apoptosis-antagonist BCL2 by MITF (McGill et al., 2002) . The phenotype of BCL2-null mice is notable for postnatal melanocyte loss, consistent with a particular requirement for this factor in survival of the melanocyte lineage (Veis et al., 1993; Nakayama et al., 1994; Kamada et al., 1995) . One of the MITF mutant alleles (MITF vit/vit ) also exhibits accelerated loss of melanocyte viability with aging (Lerner et al., 1986) , although over a longer timeframe than BCL2-null mice. An interaction between MITF and BCL2 was shown to be important for the survival of melanocytes and melanoma cells in vitro, and expression of MITF and BCL2 mRNAs was found to correlate tightly in a series of human primary melanoma specimens. These observations suggest that BCL2 may be a functionally important MITF target downstream of Kit signaling via the MAPK pathway in melanocytes. Moreover, MITF's regulation of BCL2 provides a first glimpse at why loss of MITF results in diminished melanocyte numbers, rather than pigment disturbances in viable cells.
Another suggested downstream target of MITF is TBX2 (Carreira et al., 2000) , a gene that was verified in the microarray screen for MITF targets (McGill et al., 2002) . TBX2 has been shown to suppress CDKN2A/ ARF (Jacobs et al., 2000) and thus attenuate the response of p53 (for a review see Sherr et al., 2001) , which might be of importance in melanoma, a treatment-resistant tumor in which p53 is generally found to be of wild type. Thus, like BCL2, TBX2 could represent an MITF target of MITF, which contributes to melanoma survival.
Conclusions and prospects
The intricate machinery of melanocyte-lineage cells, both during development and in neoplastic growth, seems to depend critically on the microphthalamiaassociated transcription factor, MITF, as outlined here. Given its role in sustaining the viability of this lineage, MITF emerges as a potentially attractive therapeutic target for melanoma. However, transcription factors are not typically repressable with small molecules, because of difficulties inherent in targeting protein : protein interactions, rather than catalytic moieties. For this reason, additional understanding of the pathways upand downstream of MITF may reveal more tractable therapeutic targets which, like MITF itself, are integral to the sustained growth and survival of the melanocyte lineage.
